Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

December 2, 2024

Study Completion Date

March 31, 2027

Conditions
Non Small Cell Lung Cancer Metastatic
Interventions
BIOLOGICAL

Acasunlimab

Acasunlimab will be administered intravenously (IV)

BIOLOGICAL

Pembrolizumab

Pembrolizumab will be administered IV

Trial Locations (42)

33705

Florida Cancer Center, St. Petersburg

33901

Florida Cancer Specialists - FCS South, Fort Myers

48202

Henry Ford Cancer Institute, Detroit

49503

Cancer & Hematology Centers of Western Michigan CHCWM P.C., Grand Rapids

53226

Medical College of Wisconsin, Milwaukee

95403

St. Joseph Heritage Healthcare, Santa Rosa

Unknown

Institut Bergonie, Bordeaux

Hopital Morvan CHU de Brest, Brest

Hopital Charles Nicolle Chu Rouen, Rouen

Hopital dInstruction Des Armees Begin, Saint-Mandé

Institut de Cancerologie Strasbourg Europe (ICANS), Strasbourg

Hôpital Foch, Suresnes

Gustave Roussy, Villejuif

Med.Hochschule Hannover Klinik für Pneumologie, Hanover

Universitatsklinik Giessen und Marburg Standort Giessen, Hessen

LKI Lungenfachklinik Immenhausen, Immenhausen

Department of Internal Medicine II, Regensburg

Azienda Ospedaliera Universitaria Policlinico G Rodolico San Marco, Catania

IRCCS Istituto Europeo di Oncologia, Milan

UOC Oncoematologia AOU L.Vanvitelli, Napoli

La Maddalena SPA, Palermo

IFO Regina Elena, Roma

Netherlands Cancer Institute, Amsterdam

VU University Medical Center, Amsterdam

Leids Universitair Medisch Centrum, Leiden

Erasmus MC, Rotterdam

Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc, Olsztyn

Med Polonia Sp. z o.o., Poznan

Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw

Centro Clinico Champalimaud, Lisbon

Centro Hospitalar Universitário do Porto - Hospital de Santo Antonio, Porto

Hospital Universitari Vall dHebron, Barcelona

Clinica Universidad de Navarra CUN, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Fundacion Jimenez Diaz, Madrid

MD Anderson Cancer Center, Madrid

Hospital Universitario Virgen de la Victoria, Málaga

Clinica Universidad de Navarra, Pamplona

Fundacion Instituto Valenciano de Oncologia, Valencia

Hospital Clinico Universitario de Valencia, Valencia

Cheltenham General Hospital, Cheltenham

The Christie Hospital, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Genmab

INDUSTRY

NCT05117242 - Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer | Biotech Hunter | Biotech Hunter